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Abstract
Background: In patients with patent foramen ovale (PFO) there is evidence supporting the hypothesis of a change
in right-to-left shunt (RLS) over time. Proven, this could have implications for the care of patients with PFO and a
history of stroke. The following study addressed this hypothesis in a cohort of patients with stroke and PFO.
Methods: The RLS volume assessed during hospitalisation for stroke (index event/T0) was compared with the RLS
volume on follow-up (T1) (median time between T0 and T1 was 10 months). In 102 patients with a history of
stroke and PFO the RLS volume was re-assessed on follow-up using contrast-enhanced transcranial Doppler/duplex
(ce-TCD) ultrasound. A change in RLS volume was defined as a difference of ≥20 microembolic signals (MES) or no
evidence of RLS during ce-TCD ultrasound on follow-up.
Results: There was evidence of a marked reduction in RLS volume in 31/102 patients; in 14/31 patients a PFO was
no longer detectable. An index event classified as cryptogenic stroke (P < 0.001; OD = 39.2, 95% confidence
interval 6.0 to 258.2) and the time interval to the follow-up visit (P = 0.03) were independently associated with a
change in RLS volume over time.
Conclusions: RLS volume across a PFO decreases over time, especially in patients with cryptogenic stroke. These
may determine the development of new strategies for the management in the secondary stroke prevention.
Background
Several studies identified an increased frequency of
patent foramen ovale (PFO) in patients with stroke of
undetermined aetiology, also referred to as cryptogenic
stroke (CS) [1,2]. Nevertheless the clinical relevance of
PFO in cerebral ischemic disease is still a topic of
debate [3,4]. In patients with PFO, the proposed
mechanism for stroke is paradoxical embolism (PDE)
[5,6]. PDE diagnosis can be regarded as definitive if
observed during transesophageal echocardiography
(TEE), as well if a thrombus within the PFO is found on
autopsy [7-9]. It is therefore difficult to establish a
cause-and-effect relationship between PFO and PDE
[10,11], resulting in a lack of clear guidelines for appro-
priate management to prevent recurrent stroke [12,13].
If PDE is the suspected cause of stroke, and a physiolo-
gic trajectory of PFO throughout life-time is considered,
secondary prevention measures should target further
PDE events. However, there have been anecdotal cases
reporting a reduction in RLS volume, for instance during
treatment for massive pulmonary embolism (PE) [14,15].
Whether shunt volume in patients with stroke and PFO
may change over time has not yet been proven.
The purpose of the present exploratory study was to
investigate a potential RLS change over time in a cohort
of patients with a history of stroke and PFO. Proven, it
may be regarded a pivotal finding, with an impact on
the development of new strategies for management of
these patients including an individualized delivery of
care regarding secondary prevention.
Methods
Patients
Potential patients for inclusion in the study were identi-
fied using case notes (from January 2002 to June 2007).
Eligible for study entry were patients who fulfilled the
following criteria: stroke or transient ischemic attack * Correspondence: Christian.Tanislav@neuro.med.uni-giessen.de
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enhanced transcranial Doppler/duplex ultrasound (ce-
TCD), past index event at least one month prior to
study entry.
Reviewing the case notes 169 consecutive patients
with stroke and PFO were identified. As ce-TCD detects
any type of RLS, irrespective of its location in the vascu-
lar system, we decided to include only patients who had
undergone both TEE and ce-TCD. 130 (77%) of the ori-
ginal 169 patients were identified as eligible for study
inclusion.
The study protocol was reviewed and approved by the
local ethical committee. Patients gave informed consent
prior to study participation.
Study design
In this mono-centre observational study eligible patients
were contacted by telephone and invited to participate
in the study. All patients gave consent to the study pro-
tocol. To re-assess the shunt volume across the PFO, a
ce-TCD was performed. The examiner carrying out the
ce-TCD did not have access to clinical data and initial
measurements. On follow-up, further information was
recorded for each patient: number, date and type of cer-
ebrovascular events after the index event (all events
were validated by obtaining the relevant case notes),
treatment received during follow-up period, disability
status as assessed by modified Rankin scale (mRs), time
interval between the index event and follow-up visit
(T0-T1) in months. Baseline demographic and clinical
information were obtained from case notes recorded at
the index event.
Setting
A change in shunt volume was defined as a difference of
≥20 microembolic signals (MES) or no evidence of RLS
on follow-up examination. Serial ceTCDs performed on
two subsequent days in 18 individuals with PFO, shunts
in countable range revealed an intraindividual difference
of ≤12 MES (unpublished data). Based on this observa-
tion the cut-off ≥20 MES was established. In 76% of
patients a RLS on T0 was not evident without Valsalva.
For proving a change in RLS, results obtained under
Valsalva strain were therefore considered for the
analysis.
Instrumentation
ce-TCD
A 2 MHz probe (Philips HP SONOS 5500, Philips
Healthcare, Hamburg, Germany) was used to carry out
ce-TCD. The contrast agent, based on a D-galactose
microparticle solution (Echovist™, Bayer Vital, Berlin,
Germany), was prepared according to the manufac-
turer’s instructions, and injected into a large cubital vein
of the left arm. The contrast agent was administered as
two separate boluses of 5 ml each, one while normal
respiration and the other while a 10 seconds Valsalva
strain. The Valsalva manoeuvre was practiced with the
patient before the procedure. In line with the recom-
mendations of the international consensus meeting, the
RLS was classified according to the number of MES that
appeared in the cerebral circulation (insonation of the
proximal part of the left middle cerebral artery) as mini-
mum (1-10 MES), moderate (11-30 MES) or massive
(>30 MES) or defined as a curtain pattern if an indivi-
dual MES count was not possible [16]. Assessed in our
department, repeated ce-TCD examinations revealed a
c o n c o r d a n c er a t ea sf o l l o ws: minimum shunts of 100%,
medium shunts of 95% and massive shunts of 100%
respectively (unpublished data). Examinations are routi-
nely recorded on a CD-ROM. All examinations (T0 and
T1) were evaluated offline by two experts in a standar-
dized protocol, blinded from any clinical data and the
individual chronological order. In case evaluations were
graded differently (different MES count), a consensus
read was undertaken.
TEE
TEE was performed by experienced echocardiographers
from the Department of Cardiology using a 4-7 MHz
multi-plane probe (HP Sonos 5500, Philips Healthcare,
Hamburg, Germany). The same examiner carried out
95% of the TEEs.
To detect an intracardiac shunt, 10 ml of the con-
trast agent (Echovist™, Bayer Vital, Berlin, Germany)
was administered by bolus injection into a large ante-
cubital vein. RLS was evident if the transit of micro-
bubbles from the right to the left atrium occurred
spontaneously or during a subsequent Valsalva man-
oeuvre. PFO was diagnosed when at least three micro-
bubbles were detected in the left atrium within three
heart beats after appearance in the right atrium. The
PFO classifications used were minimum (3-10 micro-
bubbles), moderate (11-30 microbubbles) and massive
(>30 microbubbles). An atrial septal aneurysm (ASA)
was diagnosed when the atrial septum extended at
least 11 mm into the left or the right atrium, or both.
An excursion of minimum 5 mm of the septum pri-
m u mi n t oe i t h e rt h el e f to rr i g h ta t r i u mw i t hr e s p e c t
to a perpendicular line to the fossa ovalis plane was
considered as hypermobile atrial septum.
Statistical evaluation
If shunt volume changed between T0 and T1, an analysis
was carried out to determine whether the change was
associated with: age, sex, index event classified as crypto-
genic stroke, use of oral anticoagulants, diagnosis of deep
vein thrombosis (DVT) on index event, diagnosis of
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delay from index event to follow-up assessment as calcu-
lated in months (T0-T1).
Non-parametric data were compared using the
Mann-Whitney 2-tailed U-test. Comparisons of dichot-
omized data between the index event and follow-up
were analyzed using Fisher’s exact test. Potential fac-
tors associated with a change in shunt volume were
identified by logistic regression analysis. For the statis-
tical analysis the SPSS Software (Statistical Package for
Social Sciences) release 15.0 (SPSS Inc., Chicago, IL,
USA) was used.
Results
Sample
All patients eligible for the study were contacted by
phone (n = 130). Nine patients (6.9%) were no longer
eligible as they had already undergone a PFO closure.
Six patients (4.6%) could not be contacted, and 11
(8.5%) declined to participate in the study. Two patients
(1.5%) were excluded from a study participation for
logistical reasons (the catheter used for the injection of
contrast agent was unsuitable). In total, 102 patients
(78.5%) were included in the study.
The median and mean age of the study population ana-
lyzed was 55.4 and 53.3 years (range, 19.7-80.2 years).
Sixty-two patients were male (60.8%). According to clas-
sification criteria published previously [17], 39 patients
(38.2%) were classified as having cryptogenic stroke
(Table 1); they were predominantly treated with oral
anticoagulation (28/39, 71.8%). In 5 patients (1.8%) a
DVT was evident at the index event.
Initial PFO and RLS assessment
At the index event, in TEE 74 patients (72.5%) had a
massive RLS; in ce-TCD 72 patients (70.6%) had a large
RLS. An ASA was identified in 23 patients (22.5%), and
a hypermobile atrial septum was identified in 26 patients
(25.5%). At least one septal abnormality was identified in
35 patients.
Overall, there was a 95% agreement between the size
of the RLS identified using ce-TCD and TEE (97/102
patients). Among patients with massive RLS, the concor-
dance rate between ce-TCD and TEE was 97.2% (72/74
patients) (Table 2).
Follow-up RLS assessment
The follow-up assessment was performed at a median of
10 months after the index event. The mean follow-up
time was 12.5 months. The follow-up period totalled
1277 patient-months of observation. During the follow-
up period, five patients (5%) had a recurrence event (2
transient ischemic attacks and 3 strokes); 40 patients
(39.2%) received oral anticoagulants. The median dis-
ability score as assessed using mRs was 1 (range: 0-3).
A small increase (difference ≤8 MES) in shunt volume
was detected in 12 patients (median 5 MES, range 3-8
MES). These patients were recorded as having an
unchanged shunt volume. In total, there was no evi-
dence of a change in shunt volume between the index
event and follow-up in 71 patients (70%).
Table 3 shows the RLS change in 31 patients who
revealed a reduction. Seventeen of these patients (54.8%)
initially presented with a curtain. In 14 patients (45.2%)
the RLS was no longer detectable on follow up. Eleven
patients (35.5%) initially assessed as having a curtain pat-
tern revealed 3-14 MES on follow-up. A reduction from
curtain pattern to no evidence for RLS was found in
6 patients (19.4%). In these patients the ce-TCDs was
repeated three times within the subsequent four months.
In all examinations no RLS could be detected. None of the
succeeding examinations revealed a RLS. As in 3 of these
patients (9.7%) a PFO-closure was considered as a thera-
peutic option, they even underwent a TEE, revealing regu-
lar findings and confirming the preceding ce-TCDs results.
Inferential statistics
For the entire study 204 ce-TCD examinations were re-
evaluated offline. In examinations with curtain pattern
(n = 62, 30.4%) and those with no evidence for RLS (n =
14, 6.9%) an interrater agreement of 100% between the 2
experts was achieved. In the remaining 128 (62.7%)
ce-TCD examinations with shunts in a countable range a
consensus read was necessary in 5 cases. For ce-TCDs in
a countable range, the interrater reliability for the MES
Table 1 Distribution of aetiologies according to the
TOAST classification
TOAST classification (n = 102) Number of patients (%)
Small artery or lacunar stroke 23 (22)
Large-artery atherosclerosis 16 (16)
Cardioembolism 16 (16)*
Uncommon, known causes of stroke 8 (8)
†
Undetermined (cryptogenic) stroke 39 (38)
*patients additionally diagnosed of atrial fibrilation
†includes causes such as artery dissection, vasculitis and anti-phospholipid
antibodies.
Table 2 Shunt size concordance TEE vs. ce-TCD assessed
at index event (n = 102)
Shunt
size
TEE at index
event
ce-TCD at index
event
Concordance
(%)
Large 74 72 72/74 (97.2)
Medium 16 19 16/19 (84.2)
Minimum 12 9 12/9 (75)
Total 97/102 (95.1)
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value (kappa = 0.95, CI = 0.93-0.97; P < 0.001).
Univariate analysis showed an association between
change in shunt volume and age, sex, presence of ASA,
i n d e xs t r o k ec l a s s i f i e da sc r y p t o g e n i ca n du s eo fo r a l
anticoagulants and. Factors initially associated in the
univariate analysis were entered into a logistic regres-
sion. Finally the time delay T0-T1 as calculated in
months from index event (P=0.03) and a cryptogenic
stroke (P < 0.001; OD = 39.2, 95% confidence interval
6.0 to 258.2) were identified as independent factors
associated with a change in RLS (Table 4).
In a subgroup analysis in patients with cryptogenic
stroke versus patients with determined aetiology, we
found a significant association of RLS reduction with an
index event of cryptogenic stroke (Table 5); 27 of 39
patients (69.2%) with cryptogenic stroke had a reduction
of RLS or functional closure of the PFO, compared to 4
of 63 patients (6.3%) with a stroke of known aetiology
(P <0 . 0 0 1 ;O D=3 1 . 2 ,9 5 %c o n f i d e n c ei n t e r v a l5 . 7t o
170.6). In this context, it is important to note that there
was no difference between the two groups as for the
time delay (T0-T1) on follow-up. Further independent
factors associated with cryptogenic stroke were: use of
oral anticoagulants (P < 0.001; OD = 10.1, 95% confi-
dence interval 2.2 to 46.7) and young age (P = 0.003).
There was no difference in stroke recurrence between
patients with RLS change on follow-up versus without a
RLS change (1/31, 3.2% vs. 4/71, 5.6%; P >0 . 9 9 ) .
Patients treated with oral anticoagulation were free of
recurrences during the follow-up period (0/40, 0% vs. 5/
62, 8.1%; P=0.15).
Discussion
Our primary finding is a reduction in RLS volume over
time in 30% of stroke patients with proven PFO. A
reduction of RLS volume or even a functional closure of
the PFO was almost exclusively found in patients with
cryptogenic stroke.
Changes in RLS across a PFO have also been proven
by other investigators, while they focused other aspects.
Anzola et al. investigated predictors for recurrent stroke
in patients with PFO and RLS [18]. When starting the
observation period the shunt volume was re-evaluated
using ce-TCD. In 8% of the patients a RLS was no
longer detected on re-examination [18], a result, which
is in line with our findings (13%). The difference (8%
vs.13%) may be explained by different baseline charac-
teristics of the selected populations.
F u r t h e re v i d e n c ef o rac h a n g eo fs h u n tv o l u m eo v e r
time can be derived from studies comparing ce-TCD
and TEE for the detection of a PFO. The highest con-
cordance rate in shunt volume was achieved when the
two procedures were carried out simultaneously [19,20].
Therefore, even when a different subsequent examina-
tion quantifies a different RLS size, this change in shunt
volume could be considered a true and accurate finding.
Although we could not directly prove shunt constancy
during the period of hospitalization, the high concor-
dance rate (95%) between TEE and ce-TCD during hos-
pitalization is an argument for such constancy in the
immediate post stroke phase.
In our study a shunt reduction across a PFO was found
in a high percentage of patients. It was predominantly
evident in patients with stroke of undetermined aetiology.
This might suggest an increased likelihood for an invol-
vement of “dynamic” PFOs in the mechanism of PDE.
For instance a moderate pressure increase in the right
atrium could facilitate an “opening” of a functionally
Table 3 PFO shunt volumes assessed by ce-TCD at index
event and follow-up visit in 31 patients who showed a
reduction (n = 102)
Patient
number
ce-TCD at index
event (MES)
ce-TCD at follow-
up (MES)
T0-T1
(months)
11 6 0 2 4
2 Curtain 0 26
3 Curtain 0 5
42 0 0 8
5 Curtain 0 6
6 Curtain 0 26
73 0 0 5
84 0 0 2 6
9 Curtain 0 24
10 20 0 3
11 25 0 36
12 15 0 12
13 Curtain 0 5
14 13 0 3
15 35 3 12
16 Curtain 3 20
17 25 3 2
18 25 3 12
19 Curtain 3 3
20 Curtain 5 40
21 Curtain 5 60
22 Curtain 5 12
23 40 6 24
24 36 6 60
25 Curtain 7 1
26 40 7 8
27 Curtain 8 1
28 Curtain 9 12
29 Curtain 9 36
30 Curtain 12 2
31 Curtain 14 48
’Curtain’ refers to a shower of microembolic signals (MES): too many to be
counted individually
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already observed during the course and treatment of an
acute massive PE [21,22]. In this context silent PE could
be suspected to cause a moderate increase in right atrial
pressure as it commonly occurs in patients with venous
embolic diseases [23,24]. While in patients with DVT
silent PE occurs in 30-60% of the cases [25-29], the fre-
quency of silent PE in patients with PFO-related stroke is
unknown. In our study a DVT diagnosed while hospitali-
zation was not associated with shunt dynamic and a
screening for silent PE was not systematically performed.
Therefore, a further clarification of the potential relation-
ship between silent PE, PDE and shunt dynamic is of high
priority. Apart from direct therapeutic consequences, it
would help to provide a better understanding of the
mechanism of PDE and PFO, respectively.
Several reports have emphasized that the volume of
RLS is a crucial risk factor for paradoxical brain embo-
lism in stroke patients. A large shunt volume in patients
with PFO and a history of stroke may be associated with
stroke recurrence [18,30,31]. Even though our results do
not prove an association with lower recurrence rates in
case of shunt reduction, the study design does not allow
a robust analysis regarding the risk of recurrence.
As therapeutic recommendations in patients with
stroke and PFO, so far are based on limited evidence
[12,32,33], our results add relevant information on
further development of new treatment strategies for sec-
ondary prevention. One single management approach,
including oral anticoagulants, anti-platelet agents, and
percutaneous or surgical closure has not yet been pro-
ven to be superior to the other [12,32-34]. Knowledge of
Table 4 Relationship between selected parameters and change in right-to-left shunt (RLS) in patients with patent
foramen ovale and a history of stroke
Total patient cohort
n = 102 (%)
RLS volume change
n = 31 (%)
No RLS volume
change n = 71 (%)
P* P
†
Age (years) median/(range) mean/(SD) 55.4/(19.7-80.2) 53.3/(15.77) 44.3/(19.7-74.4) 37.7/(14.85) 58.9/(21.4-80.2) 57.1/(14.73) < 0.001
‡ 0.881
Sex 0.04
§ 0.685
Female 40 (39.25) 17 (54.8) 23 (32.4)
Male 62 (60.8) 14 (45.2) 48 (67.6)
Cryptogenic stroke 39 (38.2) 27 (87.1) 12 (16.9) <0.001
§ <0.001
Use of anticoagulants 40 (39.2) 21 (67.7) 19 (26.8) <0.001
§ 0.969
Atrial septum aneurysm (ASA) 23 (22.5) 11 (35.5) 12 (16.9) 0.069
§ 0.165
Hypermobile atrial septum 26 (25.5) 7 (22.6) 19 (26.8) 0.806
§
Deep vein thrombosis (DVT) 5 (4.9) 1 (3.2) 4 (5.6) 0.999
§
T0-T1 (months) median/(range) mean/(SD) 10/(5-60) 12.5/(12.1) 12/(7-60) 15.6/(12.02) 9/(5-32) 10.17/(8.1) 0.081
‡ 0.037
*P value calculated in univariate analysis
†P value calculated in the logistic regression analysis
§P value based on Fisher’s exact test
‡P value based on two-tailed Mann-Whitney U-test
Table 5 Factors associated with cryptogenic stroke; subgroup comparison of patients with cryptogenic stroke versus
patients with other aetiology
Cryptogenic stroke
n = 39 (%)
Other aetiologies
n = 63 (%)
P* P
†
Age median/(range) mean/(SD) 40/(19.7-65.2) 41.9/(14.5) 63/(34-80.2) 60.4 (11.9) < 0.001
‡ < 0.001
Sex < 0.001
§ 0.102
Female 24 (61.5) 16 (25.4)
Male 15 (38.5) 47 (74.6)
RLS shunt size reduction 27 (69.2) 4 (6.3) < 0.001
§ < 0.001
Use of anticoagulants 28 (71.8) 12 (19) < 0.001
§ 0.003
Atrial septum aneurysm (ASA) 11(28.2) 12 (19) 0.33
§
Hypermobile atrial septum (HAS) 10 (25.6) 16 (25.4) < 0.999
§
ASA or HAS 16 (41) 19 (30.2) 0.29
§
Deep vein thrombosis (DVT) 3 (7.7) 2 (3.2) 0.37
§
T0-T1 median/(range) mean/(SD) 12/(6-60) 14.9/(14.4) 10/(5-45) 11.1(10.2) 0.3
‡
*P value calculated in univariate analysis
†P value calculated in the logistic regression analysis
§P value based on Fisher’s exact test
‡P value based on two-tailed Mann-Whitney U-test
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an important aspect when selecting a management strat-
egy for an individual patient. In particular, the sponta-
neous and functional closure of PFO would be of major
clinical importance, with a potential impact on an indivi-
dualised decision for or against an invasive intervention.
Due to its design, the present study is limited regard-
ing a precise determination of the time interval over
which shunt size dynamic is likely to occur. This might
be important when scheduling patients for PFO closure.
Although we demonstrated a significant association
between the time delay (median 12 versus 9 month) and
regression of the PFO shunt size, a definitive conclusion
is not possible.
The shunt evaluation on T0 represents one of the
main limitations of the present study. Even according to
the study protocol the ce-TCDs were re-evaluated off-
line, the examinations at T0 were performed under clin-
ical routine conditions. Given that in our department
ce-TCDs are performed strictly standardized, this allows
us to consider the data obtained for T0 as robust.
A high reliability of detected shunts on T0 is also sup-
ported by the remarkable shunt size concordance com-
pared to RLS assessment on TEE.
A further limitation of the present study might be
related to a methodologically determined variance of a
testing procedure; our results could be interpreted as
differences in testing between T0 and T1 versus an
actual change in shunt size. In a small case series
including patients suffering of migraine (n = 8) who
were also diagnosed of PFO, we observed no relevant
changes in RLS in consecutive examinations (2 ceTCDs
within 6 months) (unpublished data). Even though this
is not an appropriate control group for comparison in
our study, however these findings support the assump-
tion that the observed shunt reduction is caused by a
physiological process. Furthermore, in 6 patients with
reduction from an initial curtain pattern to subsequently
no RLS at T1, following consecutive ce-TDCs (3× in
4 month) confirmed the result detected at T1. Likewise,
a subsequent TEE performed in three of these patients
confirmed the functional closure; a thrombus within the
PFO, also potentially able to lead to PFO closure, was
not observed. Albeit based on few selected cases, these
findings may definitively strengthen our study results as
accurate findings which are not determined by metho-
dological differences of testing procedures.
Although our study includes a rather small number of
patients, the results are distinct in indicating an
increased likelihood for shunt reduction, especially in
patients with PFO and CS. Even when considering the
lower range of the large confidence interval, a six-folded
probability to experience a shunt reduction in case of
PFO and CS appears an intriguing result.
Considering that a shunt reduction in these patients is
of high clinical relevance, further research should focus
on the identification of factors involved in the process
of shunt dynamic. Especially circumstances which
potentially maintain a functionally “closed” PFO as well
as factors involved in “opening” of a PFO are of particu-
lar interest. In our study factors such as age and use of
anticoagulants were associated with stroke type rather
than change in shunt volume.
Conclusions
The present study demonstrates a decrease in PFO
s h u n tv o l u m eo v e rt i m e ,w i t hap r e f e r e n c et op a t i e n t s
with cryptogenic stroke. As a consequence, prior to PFO
closure, a re-examination of patients with respect to
shunt persistence appears necessary. Even if our results
are not yet sufficient to settle a definite therapeutic
strategy for an individual patient, they can be considered
to be a starting point. As it might have relevant implica-
tions in the development of new treatment strategies,
further studies are promptly required for verifying our
results. In this context a rigorous time schedule for the
follow-up assessment and a standardized setting for RLS
evaluation are major methodological issues which need
to be taken into consideration when planning further
investigations.
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